Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi Buys 159,744 Shares

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi bought 159,744 shares of the firm’s stock in a transaction dated Monday, April 22nd. The shares were acquired at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the transaction, the director now directly owns 777,384 shares in the company, valued at $2,433,211.92. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Zura Bio Stock Performance

Shares of ZURA stock opened at $3.31 on Thursday. The stock’s fifty day moving average is $3.21 and its two-hundred day moving average is $4.04. Zura Bio Limited has a fifty-two week low of $2.00 and a fifty-two week high of $14.00.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reiterated an “outperform” rating and set a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $16.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP purchased a new position in Zura Bio in the 3rd quarter valued at $65,000. Forefront Analytics LLC purchased a new position in Zura Bio in the 3rd quarter valued at $95,000. Bank of New York Mellon Corp purchased a new position in Zura Bio in the 3rd quarter valued at $224,000. Raymond James & Associates lifted its holdings in Zura Bio by 14.0% in the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after purchasing an additional 9,481 shares in the last quarter. Finally, Eisler Capital US LLC purchased a new position in Zura Bio in the 3rd quarter valued at $660,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.